Here are 1-3 brief analogies for Envoy Medical (COCH):

• Like Cochlear Limited, but offering solutions for the entire hearing loss spectrum.
• A specialized Medtronic, focused exclusively on medical technologies for hearing health.

• Hearing Aids: Devices designed to amplify sound and improve hearing for individuals with hearing loss.
• Esteem Middle Ear Implants: Surgically implanted devices that utilize the natural components of the ear to provide enhanced hearing.
• Auditory Osseointegrated Implants (Bone Conduction Devices): Implants that transmit sound vibrations directly to the inner ear through bone, bypassing damaged parts of the outer and middle ear.
• Acclaim Cochlear Implants: Electronic medical devices that can provide a sense of sound to individuals with severe to profound sensorineural hearing loss.

Envoy Medical (symbol: COCH) primarily sells its medical technologies for the hearing loss spectrum to other companies and institutions within the healthcare sector rather than directly to individuals. Due to the fragmented nature of the healthcare provider market and typical sales channels for medical devices, Envoy Medical does not identify a few major publicly traded customer companies that account for a significant portion of its revenue.

Instead, its customer base comprises a broad network of healthcare providers and distributors. These include:

• Hospitals and Academic Medical Centers: These institutions are customers for Envoy Medical's surgical implants (Esteem middle ear implants, bone conduction devices, Acclaim cochlear implants) and associated services, primarily through their Ear, Nose, and Throat (ENT) departments and audiology clinics.
• Private Audiology Practices and Hearing Healthcare Professionals: These practices dispense Envoy Medical's hearing aids and manage patients for their implantable devices.
• Private Ear, Nose, and Throat (ENT) Surgeon Practices: Individual ENT surgeons in private practice are key customers, particularly for the company's implantable medical devices.
• Independent Distributors: Particularly in international markets, Envoy Medical utilizes a network of independent distributors responsible for sales, marketing, and support within their respective territories.

Brent Lucas

Chief Executive Officer

Mr. Lucas has served as the CEO of Envoy Medical since November 2015. He possesses nearly two decades of direct experience within the implanted medical device sector of the hearing industry. Starting as an intern, he advanced through various roles, including General Counsel and Business Development Manager, before becoming CEO and a Board Member. He is a long-term shareholder, with his parents having first invested in St. Croix Medical (Envoy Medical's original name) in 1995. Mr. Lucas led the company to go public through a SPAC in 2023. He holds a Bachelor's degree from the University of St. Thomas and a JD from Mitchell Hamline School of Law. His father was an executive who significantly contributed to the growth of Bio-Techne, an international biotechnology company. Mr. Lucas has expressed a view that building companies solely for acquisition is a mistake, emphasizing long-term growth over quick sales.

Robert Potashnick

Interim Chief Financial Officer

Mr. Potashnick was appointed interim Chief Financial Officer of Envoy Medical, effective June 23, 2025. Prior to this role, he provided consulting services through Oasis Business Consulting since October 2024. His previous experience includes serving as CFO of Flutterbee Education Group from January 2024 to October 2024, and as CFO of FOXO Technologies Inc. from January 2021 to September 2023. Earlier in his career, he held finance and capital planning positions at UnitedHealth Group between 2017 and 2020, and worked as a certified public accountant at PricewaterhouseCoopers LLP from 2010 to 2017. Mr. Potashnick earned a Bachelor of Arts in Economics from Northwestern University, a Master's Degree in Accountancy from the University of Illinois, and an MBA in Finance and Strategy from DePaul University.

Karin Simonson

Vice President, General Counsel & Secretary

Karin Simonson has served as Envoy Medical's Vice President, General Counsel & Corporate Secretary since December 2023. Before joining Envoy Medical, she was General Counsel for Monarch Healthcare Management from April 2023 to December 2023. Ms. Simonson brings over 20 years of diverse in-house counsel experience, with a focus on the medical device industry for the past 15 years. She began her legal career in commercial litigation over 25 years ago. She has been a board member of the Association of Corporate Counsel (ACC) Minnesota Chapter for nine years. Ms. Simonson holds a BS, magna cum laude, from the University of Minnesota-Twin Cities, and a JD, magna cum laude, from Mitchell Hamline School of Law.

Tom Hoegh

Vice President, Research and Development

Mr. Hoegh brings over 30 years of experience in the medical device industry, specializing in the development and support of active implantable devices, including neuromodulation systems. He has led engineering teams at several notable companies, including Nuvectra, ICU/Smiths Medical, Medtronic, and Apnex Medical. Mr. Hoegh holds dual Bachelor of Science degrees in Mechanical Engineering and Chemistry from Valparaiso University and a Master's in Technology Management from the University of St. Thomas.

The key risks to Envoy Medical's business include:

1. Financial Instability and Need for Continued Funding: Envoy Medical is an early commercial-stage company characterized by significant cash burn and a history of net losses. The company has reported negative shareholder equity and a limited cash runway. While recent financing efforts have secured capital and have the potential to fund operations through 2028-2029, this is partially dependent on the exercise of milestone-linked warrants, which introduces an element of uncertainty. The company anticipates continued net losses due to substantial research and development (R&D) and marketing costs.
2. Regulatory Approval and Reimbursement Challenges: The successful commercialization of Envoy Medical's flagship Acclaim cochlear implant is contingent upon receiving U.S. Food and Drug Administration (FDA) approval. The Acclaim is currently an investigational device, with a PMA submission expected by 2028, and there is no guarantee of approval. Any delays in this process would be costly and impact the company's trajectory. Furthermore, its commercially available Esteem middle ear implant has faced limited market success due to its classification as a hearing aid by Medicaid, which restricts insurance reimbursement, and a change in this policy is not assured.
3. Market Acceptance and Competition: Envoy Medical operates in a competitive landscape dominated by established players. The company faces the significant challenge of gaining market acceptance for its innovative, fully implantable hearing devices, especially given that market demand for partially implanted inner ear devices has historically been low. Convincing the risk-averse medical community to adopt new technology from a relatively unknown company over long-standing solutions from competitors with diversified portfolios, global distribution networks, and deep industry relationships is a substantial hurdle.

The rise and increasing adoption of over-the-counter (OTC) hearing aids represents a clear emerging threat. The FDA finalized rules for OTC hearing aids in August 2022, allowing consumers to purchase these devices directly without a medical exam or prescription. This regulatory change has led to increased competition from new entrants, including major retailers and consumer electronics companies, offering more accessible and often lower-cost options. This shift could impact Envoy Medical's traditional hearing aid business by increasing price pressure and potentially reducing market share for devices requiring professional fitting and prescription, thereby altering the established business model in a segment of the hearing health market.

Envoy Medical (COCH) Addressable Market Sizes

Envoy Medical, Inc. focuses on several segments within the hearing health market, including hearing aids, middle ear implants, bone conduction devices, and cochlear implants. The addressable markets for these products are substantial.

• Hearing Aids: The global hearing aids market size was estimated at USD 15.11 billion in 2025 and is projected to grow to USD 37.81 billion by 2034, exhibiting a Compound Annual Growth Rate (CAGR) of 11.00% during the forecast period. Another estimate places the global market at USD 9.08 billion in 2025, with a projection to reach USD 17.87 billion by 2035 at a CAGR of 7.05%. Europe held a major revenue share in the hearing aids market, while North America also shows strong growth potential.
• Esteem Middle Ear Implants: The global middle ear implants market was valued at USD 55.35 million in 2025 and is expected to reach USD 102.29 million by 2033, growing at a CAGR of 7.98%. Another source indicates the global middle ear hearing implant market was valued at US$12.36 billion in 2024 and is forecast to reach US$21.31 billion by 2030, with a CAGR of 8.1%. North America dominated the middle ear implants market in 2025, characterized by advanced healthcare infrastructure and high per capita healthcare spending.
• Bone Conduction Devices (including auditory osseointegrated implants): The global bone conduction devices market is projected to expand robustly, valued at USD 1.27 billion in 2024 and expected to reach USD 2.11 billion by 2030. The bone conduction hearing aids market alone was valued at USD 246.87 million in 2024 and is expected to reach USD 616.07 million by 2032, at a CAGR of 12.11%. North America is anticipated to hold the largest share of this market.
• Acclaim Cochlear Implants: The global cochlear implant market size was estimated at USD 2.28 billion in 2025 and is expected to reach USD 4.67 billion by 2033, growing at a CAGR of 9.50%. Another estimate states the global market was valued at US$2.80 billion in 2024 and is projected to advance to US$4.73 billion by 2030, at a CAGR of 9.2%. North America held the largest share of the global cochlear implant market in 2025. Specifically for the U.S. market, it is estimated that approximately 2.8 million adults are eligible for cochlear implants, with fewer than 5% currently receiving them, indicating a significant underpenetrated market.

Envoy Medical, Inc. (COCH) is poised for future revenue growth over the next 2-3 years, primarily driven by advancements in its innovative, fully implanted hearing technologies and strategic market expansion. The key drivers are:

1. Advancement towards commercialization of the fully implanted Acclaim Cochlear Implant: The company has made significant progress with its investigational Acclaim cochlear implant, completing enrollment in its pivotal clinical trial in March 2026. Envoy Medical anticipates submitting its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) in the second quarter of 2027. This fully implanted device is designed to address severe to profound sensorineural hearing loss and has the potential to tap into a large, currently underserved market of approximately 2.8 million eligible U.S. adults, of whom fewer than 5% currently receive cochlear implants due to the aesthetic and practical barriers of external components.
2. Increased market access and improved reimbursement for the Esteem Middle Ear Implant: The Esteem fully implanted active middle ear implant (FI-AMEI) is already FDA-approved and commercially available in the U.S.. Envoy Medical is actively pursuing market access efforts and anticipates potential reimbursement updates for the Esteem device. Notably, new CPT codes for fully implanted active middle ear implants became effective in July (presumably 2025), which are expected to further the efforts for Esteem reimbursement.
3. Penetration of the large, untapped market for fully implanted hearing solutions: Envoy Medical is strategically positioned to capture a significant share of the hearing loss market by providing fully implanted devices that eliminate external hardware. The company believes this approach will overcome key barriers to adoption, such as visible stigma and inconvenience, appealing to the estimated 95% of eligible adults who have not yet received cochlear implants.
4. Growth in replacement component sales for the Esteem Middle Ear Implant: For its commercially available Esteem implant, Envoy Medical has already seen revenue growth driven by sales of replacement components. As the installed base of Esteem implants grows, this recurring revenue stream is expected to continue contributing to the company's overall revenue growth.

Share Issuance

• In February 2026, Envoy Medical closed an upsized public offering, raising approximately $30.0 million in gross proceeds, with the potential for an additional $48.0 million if milestone-linked warrants are fully exercised. The offering included 75,000,000 Class A shares (or pre-funded warrants) and accompanying Series A-1 and A-2 warrants.
• In September 2025, the company completed a registered direct offering of 1,908,402 shares of Class A common stock at $1.31 per share, yielding approximately $2.5 million in gross proceeds. Concurrently, it issued unregistered warrants to purchase up to 5,725,206 shares, which could generate an additional $7.5 million if fully exercised.
• In October 2025, Envoy Medical issued October Private Placement Warrants to purchase up to an aggregate of 9,022,572 shares of common stock in a concurrent private placement.

Inbound Investments

• The February 2026 upsized public offering was anchored by new investor Nantahala Capital and long-time shareholder Glen Taylor, with participation from healthcare funds like Broadfin Holdings, and existing investors including board members and management.
• As part of the February 2026 offering, significant shareholder Glen Taylor acquired 18,750,000 shares of Class A Common Stock for $7,500,000.

Capital Expenditures

• Envoy Medical reported capital expenditures of $980K in Q3 2025.
• Net proceeds from the February 2026 offering are intended for working capital and general corporate purposes to fund operations during the FDA pivotal clinical study for its Acclaim cochlear implant.
• The financing secured in February 2026 is anticipated to fund the company through its pivotal clinical trial, regulatory submission, and potentially into initial commercialization through 2028 and into 2029, indicating significant planned expenditures for product development and market launch.